TLSA•benzinga•
Tiziana Life Sciences Announced That Dosing Has Commenced At The Fourth Clinical Site In Its Ongoing Phase 2 Trial Evaluating Intranasal Foralumab In Patients With Non-active Secondary Progressive Multiple Sclerosis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 23, 2025 by benzinga